Indications
Graftcept in combination with corticosteroids and either ciclosporin or tacrolimus is indicated for- Prophylaxis of acute organ rejection and treatment of first or refractory organ rejection in patients receiving allogeneic renal transplants. Prophylaxis of acute organ rejection in patients receiving allogeneic cardiac transplants. ... Read moreGraftcept in combination with corticosteroids and either ciclosporin or tacrolimus is indicated for- Prophylaxis of acute organ rejection and treatment of first or refractory organ rejection in patients receiving allogeneic renal transplants. Prophylaxis of acute organ rejection in patients receiving allogeneic cardiac transplants. Prophylaxis of acute organ rejection in patients receiving allogeneic hepatic transplants. Graftcept is indicated for induction and maintenance therapy of patients with Class III-V lupus nephritis (diagnosed according to International Society of Nephrology/Renal Pathology Society classification.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Mechanism of Action: Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA). MPA is a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and it therefore inhibits the de novo pathway of guanosine nucleotide synthesis. The way MPA inhibits the enzymatic activity of IMPDH appears to be related to its ability to structurally mimic both the nicotinamide adenine dinucleotide cofactor and a catalytic water molecule. This prevents the oxidation of IMP to xanthose-5'-monophosphate, which is the committed step in de novo guanosine nucleotide biosynthesis. MPA has more potent cytostatic effects on lymphocytes than on other cells because T and B lymphocytes depend critically on de novo purine synthesis for their proliferation, whereas other cell types can rely on salvage pathways instead.
Pharmacodynamics: Mycophenolic acid, the active metabolite of mycophenolate mofetil, is a non-competitive, reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). Inhibiting IMPDH blocks the de novo synthesis of guanosine nucleotides, which are necessary substrates for DNA and RNA synthesis. Unlike other cell types, which can use the salvage pathway, B and T lymphocytes depend on the de novo pathway to generate guanosine. Data from in vitro studies show that mycophenolic acid and/or mycophenolate mofetil inhibit mixed lymphocyte responses and human peripheral blood lymphocyte proliferation induced by a variety of mitogens and antigens. Mycophenolic acid reduces intracellular pools of guanosine triphosphate (GTP) and deoxyguanosine triphosphate (dGTP) in mitogen-stimulated human peripheral blood monocytes or T lymphocytic cell lines, but it has no effect on GTP concentrations in human neutrophils.
Pregnancy & Breastfeeding
Mycophenolate Mofetil should not be used during pregnancy or while breastfeeding. It has not been established as safe for use during labor and delivery either.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.
Side Effects & Interactions
Side Effects
No side-effect data recorded yet.